C53.9
Conditions
Interventions
Group 1: Immunohistochemical evaluation of PSMA expression in malignant cervical tissue
Group 2: Immunohistochemical evaluation of the PSMA status of healthy cervical tissue and its malignant precurso
Sponsors
Universitätsklinikum FreiburgKlinik für Frauenheilkunde
Eligibility
Sex/Gender
Female
Age
0 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients with a histologically secured invasive cervical carcinoma are included in this study . The cancerous pre-stages surrounding the Tumor (cervical intraepithelial neoplasia, adenocarcinoma in situ) are also investigated.
Exclusion criteria
Exclusion criteria: - no declaration of consent - other oncological disease - adenosquamous, neuroendocrine (large or small cell), clear-line or serous-papillary carcinoma - Cytostatic or radiotherapy administered before tissue sampling
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Description of the PSMA expression within the cervix and cervical carcinoma and its malignant precursors on previously removed tissue, using immunohistochemistry and immunofluorescence, as well as proteomic analyses if necessary. | — |
Secondary
| Measure | Time frame |
|---|---|
| Depending on the PSMA status (both tumor cells and Tumorneovasculature): - overall survival (OS) - Disease free survival (dfs) Clinical parameters: - Age at time of diagnosis, menopause status, FIGO stage at time of diagnosis, distant metastasis, body mass index, family history, birth rate, postoperative radio- or chemotherapy. Histopathological parameters: - pTNM stage, histological subtype (squamous cell carcinoma), grading, lymph vessel, vein and perineural vaginal infiltration, deep stroma invasion (>66%), three dimensional tumor size in centimeters, HPV status (positive/negative). | — |
Countries
Germany
Contacts
Public ContactPeter Bronsert
Universitätsklinikum FreiburgDepartement für klinische Pathologie
Outcome results
None listed